Live After an Epithelial Ovarian Cancer: Multidisciplinary Assessment of Effects and Long-term Remission in Patients Needs.
This trial is active, not recruiting.
|Condition||epithelial ovarian cancer|
|Sponsor||Centre Francois Baclesse|
|Collaborator||Ligue contre le cancer, France|
|Start date||December 2014|
|End date||July 2016|
|Trial size||179 participants|
|Trial identifier||NCT02323568, VIVROVAIRE 2|
This project is part of a large multicenter multidisciplinary program that will thoroughly explore the needs and difficulties of patients with BCR as well as those involved in their care. The results of this research program will propose recommendations for better structure and understand the follow up of these patients.
From the limited data in the literature, the long-term remission in patients with ovarian cancer reported a significant and persistent fatigue, poor QoL, disorders of sexuality as well as somatic and mental illness; consumption is also a medical records for these patients.
In this context, our team has initiated a large case-control study to assess fatigue (identified major problem in the long-term remission in patients with ovarian cancer), QoL and rehabilitation of patients in remission from an epithelial ovarian cancer (regardless of the stage of cancer at diagnosis, early or advanced) 3 years after the initial treatment, compared with women of the same age without ovarian cancer or serious chronic disease , from the general population.
Patients and controls complement standardized and validated self-administered questionnaire (part 1). This study investigated 215 patients in long remission from ovarian cancer compared to 215 women of the same age without cancer. Recruitment of patients is currently underway, in close collaboration with teams from the Group GINECO very involved in this project.
Following this step, an additional component is planned: it is to offer patients who participated in part 1, a specific gynecological consultation to assess in detail the effects of the treatments in order to better meet the needs of patients .dropoff window
|United States||No locations recruiting|
|Other countries||No locations recruiting|
|Besançon, France||CHU||no longer recruiting|
|Bordeaux, France||Institut Bergonie||no longer recruiting|
|Bordeaux, France||Polyclinique Bordeaux Nord||no longer recruiting|
|Caen, France||CHU||no longer recruiting|
|Caen, France||Centre François Baclesse||no longer recruiting|
|Cholet, France||Centre Hospitalier||no longer recruiting|
|La Tronche, France||CHU Grenoble||no longer recruiting|
|Lille, France||Centre Oscar Lambret||no longer recruiting|
|Lyon, France||Centre Léon Bérard||no longer recruiting|
|Montpellier, France||Institut régional du cancer||no longer recruiting|
|Nice, France||Centre Antoine Lacassagne||no longer recruiting|
|Paris, France||Hôpital Cochin||no longer recruiting|
|Paris, France||Hôpital Européen Georges Pompidou||no longer recruiting|
|Reims, France||Institut Jean Godinot||no longer recruiting|
|Saint Herblain, France||Institut de Cancérologie de l'Ouest||no longer recruiting|
|Senlis, France||GHPSO||no longer recruiting|
|Vandoeuvre les Nancy, France||Institut de cancérologie de Lorraine||no longer recruiting|
|Villejuif, France||Institut Gustave Roussy||no longer recruiting|
|Intervention model||single group assignment|
Physical sequelae measured by the functional and biological effects
time frame: At inclusion
Female participants at least 18 years old.
Inclusion Criteria: - Age> 18 years; - Patients who received optimal treatment (surgery, chemotherapy ...) - Patients with epithelial ovarian cancer after first-line treatment; - Patients without other cancer (except basal cell skin carcinoma and breast cancer in situ); - Patients without clinical relapse, biological or radiological documented at least 3 years after the initial treatment (from the end date of first line chemotherapy); - The interviews treatments are not recognized in the period; - Patients may be included regardless of the stage of cancer at diagnosis (early or late) - Patients who have signed their written consent to participate in the part 2 of the study Vivrovaire; - Patients who participated in part 1 of Vivrovaire study. Exclusion Criteria: - Psychiatric pathology can disrupt the conduct of the study or to prevent the interpretation of results; - Persons deprived of liberty; - Major subject to a measure of legal protection or unable to consent.
|Official title||Live After an Epithelial Ovarian Cancer: Multidisciplinary Assessment of Effects and Long-term Remission in Patients Needs.|
|Principal investigator||Florence JOLY, PhD|
Call for more information